Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.
Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y, Yonezawa H, Asai K, Fukuhara N, Sugiyama K, Shinojima N, Kitagawa J, Aoi A, Nishikawa R. Narita Y, et al. Among authors: aoi a. Neuro Oncol. 2021 Jan 30;23(1):122-133. doi: 10.1093/neuonc/noaa145. Neuro Oncol. 2021. PMID: 32583848 Free PMC article. Clinical Trial.
Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies.
Munakata W, Ando K, Yokoyama M, Fukuhara N, Yamamoto K, Fukuhara S, Ohmachi K, Mishima Y, Ichikawa S, Ogiya D, Aoi A, Hatsumichi M, Tobinai K. Munakata W, et al. Among authors: aoi a. Int J Hematol. 2023 Apr;117(4):553-562. doi: 10.1007/s12185-022-03514-6. Epub 2022 Dec 28. Int J Hematol. 2023. PMID: 36576659 Free PMC article. Clinical Trial.
Karnofsky Performance Status and quality of life in patients with relapsed or refractory primary CNS lymphoma from a phase I/II study of tirabrutinib.
Arakawa Y, Narita Y, Nagane M, Mishima K, Terui Y, Yonezawa H, Asai K, Fukuhara N, Sugiyama K, Shinojima N, Aoi A, Nishikawa R. Arakawa Y, et al. Among authors: aoi a. Neurooncol Adv. 2023 Sep 14;5(1):vdad109. doi: 10.1093/noajnl/vdad109. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37744697 Free PMC article.
Three-year follow-up analysis of phase 1/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma.
Yonezawa H, Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y, Asai K, Fukuhara N, Sugiyama K, Shinojima N, Aoi A, Nishikawa R. Yonezawa H, et al. Among authors: aoi a. Neurooncol Adv. 2024 Apr 22;6(1):vdae037. doi: 10.1093/noajnl/vdae037. eCollection 2024 Jan-Dec. Neurooncol Adv. 2024. PMID: 38690230 Free PMC article.
Doping control analyses during the Tokyo 2020 Olympic and Paralympic Games.
Okano M, Ikekita A, Sato M, Inoue T, Kageyama S, Akiyama K, Aoi A, Miyamoto A, Momobayashi A, Ota M, Ishige M, Sakurai H, Shiomura S, Takemine M, Watanabe Y, Hikota T. Okano M, et al. Among authors: aoi a. Drug Test Anal. 2022 Nov;14(11-12):1836-1852. doi: 10.1002/dta.3381. Epub 2022 Oct 18. Drug Test Anal. 2022. PMID: 36208085
Exposure levels of organophosphate pesticides in Japanese diapered children: Contributions of exposure-related behaviors and mothers' considerations of food selection and preparation.
Oya N, Ito Y, Ebara T, Kato S, Hioki K, Aoi A, Ueyama J, Oguri T, Shoji N, Sugiura-Ogasawara M, Saitoh S, Kamijima M. Oya N, et al. Among authors: aoi a. Environ Int. 2020 Jan;134:105294. doi: 10.1016/j.envint.2019.105294. Epub 2019 Nov 12. Environ Int. 2020. PMID: 31731003 Free article.
19 results